NRIX (Nurix Therapeutics) Total Stockholders Equity: $402.63 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
59 GF Score
Price $26.13
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Total Stockholders Equity?

Nurix Therapeutics NRIX -0.08% 59 Total Stockholders Equity is $402.63 Mil as of May. 2026. GuruFocus rates NRIX with a GF Score™ of 59/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Nurix Therapeutics's Total Stockholders Equity for the quarter that ended in May. 2026 was $402.63 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nurix Therapeutics's Book Value per Share for the quarter that ended in May. 2026 was $3.88. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nurix Therapeutics's Debt-to-Equity for the quarter that ended in May. 2026 was 0.14.

Nurix Therapeutics  (NAS:NRIX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nurix Therapeutics's Book Value per Share for the quarter that ended in May. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(402.627-0)/103.702
=3.88

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nurix Therapeutics's Debt-to-Equity for the quarter that ended in May. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.221 + 54.922) / 402.627
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics Total Stockholders Equity Related Terms

Nurix Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Nurix Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nurix Therapeutics Total Stockholders Equity Chart

Nurix Therapeutics Annual Data
Trend Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Total Stockholders Equity
Get a 7-Day Free Trial 342.30 303.70 200.49 526.99 538.75

Nurix Therapeutics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 447.60 372.25 538.75 480.89 402.63
NRIX
59GF Score
Nurix Therapeutics Inc NRIX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $402.63 Mil mean?
Nurix Therapeutics (NRIX) has a Total Stockholders Equity of $402.63 Mil as of May. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nurix Therapeutics and its competitors.
Is Nurix Therapeutics' Total Stockholders Equity too high?
Nurix Therapeutics' current Total Stockholders Equity is $402.63 Mil. Overall, Nurix Therapeutics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Total Stockholders Equity compare to ATAI and SLS?
Nurix Therapeutics' Total Stockholders Equity of $402.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Nurix Therapeutics and its competitors. Nurix Therapeutics's current Total Stockholders Equity is $402.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $26.13 — trading 244.7% above its estimated fair value. The current Total Stockholders Equity is $402.63 Mil. Nurix Therapeutics' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Total Stockholders Equity is $402.63 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $26.13 is trading 244.7% above its estimated GF Value™ of $7.58. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Total Stockholders Equity: $402.63 Mil
  • GF Value™: $7.58 vs. price of $26.13 (244.7% above fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
59GF Score

Get the complete analysis for NRIX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.13
Price
$7.58
GF Value